11,855 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Generali Investments Management Co LLC

Generali Investments Management Co LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel.com reports. The fund purchased 11,855 shares of the biopharmaceutical company’s stock, valued at approximately $1,095,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after buying an additional 841,776 shares during the period. Wellington Management Group LLP increased its stake in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the period. FMR LLC increased its stake in Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after buying an additional 14,680,161 shares during the period. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after buying an additional 249,804 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Mizuho raised their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Morgan Stanley raised their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, March 11th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Gilead Sciences Trading Down 1.8 %

Gilead Sciences stock opened at $110.23 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $102.63 and a two-hundred day moving average price of $93.38. The firm has a market capitalization of $137.27 billion, a price-to-earnings ratio of 297.92, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.